How does a new cancer drug go from laboratory discovery to hospital treatment? Professor Ruth Plummer FMedSci shares her story taking an ovarian cancer treatment from an academic drug discovery project to a treatment now licensed in the USA and Europe.
Professor Plummer is part of the team that discovered the ovarian cancer drug rucaparib (Rubraca®). Rucaparib inhibits the enzyme poly ADP ribose polymerase (PARP), and offers hope to the hundreds of women who are diagnosed each year with inoperable tumours.
Professor Plummer is Professor of Experimental Cancer Medicine at Newcastle University.
Follow her on Twitter [ Ссылка ]
Professor Plummer gave this presentation ‘Rucaparib – a story of academic cancer drug discovery and development’ as part of the Academy of Medical Sciences New Fellow's Admissions Day 2018, held on 27 June. On this day, the Academy welcomed newly elected Fellows for their formal admission.
Read more about Professor Plummer's work
[ Ссылка ]
For more information about New Fellows Day 2018, visit
[ Ссылка ]
Find the Academy of Medical Sciences online:
Website: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
